Objective: BCMA- or GPRC5D-directed CD3 bispecific antibodies are important T-cell–redirecting therapies for relapsed/refractory multiple myeloma (RRMM). We evaluated their efficacy, safety, and certainty of evidence. Methods: We searched the Cochrane Library, Embase, PubMed, Scopus, and Web of Science from inception to February 5, 2026. Prospective clinical trials and real-world studies of BCMA×CD3 or GPRC5D×CD3 bispecific antibodies in RRMM with extractable efficacy and safety data were included. Main efficacy outcomes were progression-free survival (PFS), stringent complete response (sCR), complete response (CR), complete response or better (≥CR), very good partial response or better (≥VGPR), and overall response rate (ORR). Safety outcomes included cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), infection, neutropenia, anemia, and thrombocytopenia. Single-arm proportional meta-analyses, sensitivity analyses, meta-regression, and subgroup analyses were performed using STATA/MP 18.0. Methodological quality and evidence certainty were assessed using MINORS and GRADE, respectively. Results: Fifteen studies, including 17 independently extractable cohorts and 1,900 patients, were analyzed. The pooled PFS was 8.76 months (95% CI, 6.82–11.13). The pooled rates of sCR, CR, ≥CR, ≥VGPR, and ORR were 28.7%, 18.1%, 38.2%, 51.0%, and 65.9%, respectively. The pooled incidences of CRS, ICANS, infection, grade ≥3 infection, neutropenia, and grade ≥3 neutropenia were 67.5%, 9.7%, 60.3%, 38.3%, 54.7%, and 42.6%, respectively. MINORS showed moderate-to-high methodological quality. GRADE showed low-to-very low certainty of evidence. Conclusion: BCMA- or GPRC5D-directed CD3 bispecific antibodies showed clinically meaningful antitumor activity in RRMM. However, current evidence is mainly from single-arm trials and retrospective real-world studies, and certainty of evidence remains low to very low. These findings should be interpreted cautiously, with particular attention to infection and neutropenia in clinical practice.